Brainstorm Cell Therapeutics INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OQB
SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose Nearly 10% Stake in Brainstorm Cell Therapeutics
Investment firm Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Brainstorm Cell Therapeutics Inc., held for investment purposes.
OQB
SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Passive Stake in Brainstorm Cell Therapeutics
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.99% in Brainstorm Cell Therapeutics Inc. as of December 31, 2024.